Cardio3 BioSciences (C3BS) closed a €19 million (US$25 million) investment round to fund an ongoing European Phase III trial of its stem cell therapy for ischemic heart failure, C-Cure. Just €7 million of the total represents new money, however. The remainder comprises an equity conversion of existing loans.
Cosmo Pharmaceuticals SpA landed a hefty chunk of upside, that all-too-elusive commodity, by grossing $89.2 million from a sale of Santarus Inc. stock. The transaction will enable the already-profitable company to begin paying dividends to its shareholders.
DUBLIN, Ireland – Elan Corp. plc is putting down a $1 billion bet that the respiratory franchise shared by Theravance Inc. and GlaxoSmithKline plc will pay generous dividends over the next decade. Elan is acquiring a 21 percent stake in Theravance's future royalty streams from four drugs that are partnered with London-based GSK.
DUBLIN, Ireland – Elan Corp. plc is putting down a $1 billion bet that the respiratory franchise shared by Theravance Inc. and GlaxoSmithKline plc will pay generous dividends over the next decade. Elan is acquiring a 21 percent stake in Theravance's future royalty streams from four drugs that are partnered with London-based GSK.
Cardio3 BioSciences (C3BS) closed a €19 million ($25 million) investment round to fund an ongoing European Phase III trial of its stem cell therapy for ischemic heart failure, C-Cure. Just €7 million of the total represents new money, however. The remainder comprises an equity conversion of existing loans.
GlaxoSmithKline plc's initiative on data transparency took a decisive step forward Tuesday as the company switched on the website that will act as the point of access to its vast repositories of clinical data and named the independent review panel who will control that access.
Oxford BioTherapeutics (OBT) Ltd. entered a target validation deal with Boehringer Ingelheim GmbH that will offer near-term revenues, with the added prospect of long-term development milestones and product royalties.
Genticel SA raised €18.2 million (US$23.6 million) in a Series C round led by Wellington Partners, to move ProCervix, its bivalent therapeutic vaccine for combating human papillomavirus (HPV) infection into Phase II trials.
Oxford BioTherapeutics (OBT) Ltd. entered a target validation deal with Boehringer Ingelheim GmbH that will offer near-term revenues, with the added prospect of long-term development milestones and product royalties.
DUBLIN, Ireland – Opsona Therapeutics Ltd. raised €33 million (US$43.2 million) in a Series C funding round to take forward a first-in-class Toll-like receptor 2 (TLR-2) inhibitor, OPN-305, into a Phase II trial for preventing delayed graft function (DGF) in high-risk kidney transplant patients.
